\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ sphincter\\ tone\\,\\ guaiac\\ negative\\,\\ diminished\\ light\\ touch\\ and\\ temperature\\ sensation\\ along\\ left\\ penis\\ and\\ scrotum\\,\\ otherwise\\ normal\\ exam\ \(1\)\
\-\ chondrosarcoma\\ is\\ managed\\ similarly\\ to\\ osteosarcoma\\,\\ with\\ radical\\ surgery\\ being\\ the\\ treatment\\ of\\ choice\\.\\ \\ when\\ only\\ excision\\ is\\ employed\\,\\ 90\\%\\ of\\ tumors\\ recur\\ locally\\.\\ \\ the\\ overall\\ 10\\ year\\ survival\\ rate\\ following\\ surgery\\ is\\ approximately\\ 65\\%\\.\\ \\ radiation\\ therapy\\ as\\ the\\ primary\\ modality\\ for\\ chondrosarcoma\\ is\\ limited\\.\\ \\ pulmonary\\ metastasis\\ occur\\,\\ but\\ the\\ value\\ of\\ chemotherapy\\ is\\ not\\ well\\ established\\.\\ \\ doxorubicin\\ yields\\ a\\ response\\ rate\\ of\\ only\\ 17\\%\\ for\\ metastatic\\ chondrosarcoma\\.\ \(0\)\
\-\ 1\\)\\ plain\\ films\\-\\ normal\\ si\\ joints\\,\\ ill\\ defined\\ lucent\\ area\\ over\\ lower\\ left\\ sacrum\\,\\ two\\ sacral\\ neural\\ foramina\\ on\\ left\\ widened\\ with\\ erosions\\ of\\ borders\ \(0\)\
\-\ 2\\)\\ ct\\-\\ mass\\ left\\ side\\ of\\ sacrum\\,\\ left\\ side\\ of\\ s1\\ encroaching\\ on\\ left\\ side\\ neural\\ foramen\\,\\ normal\\ vertebral\\ bodies\ \(0\)\
\-\ 3\\)\\ mri\\-\\ infiltrating\\ lesion\\ with\\ high\\ t2\\ signal\\ intensity\\ within\\ body\\ of\\ sacrum\\ infiltrating\\ into\\ the\\ epidural\\ space\ \(0\)\
\-\ high\\-grade\\ chondroid\\ neoplasm\ \(0\)\
\-\ metastatic\\ disease\\,\\ primary\\ bone\\ tumor\\,\\ lymphoma\\,\\ multiple\\ myeloma\\,\\ giant\\ cell\\ tumor\\,\\ and\\ chondroma\ \(1\)\
\-\ 45\\ y\\/o\\ white\\ male\\ initially\\ presented\\ with\\ five\\ week\\ hx\\ of\\ left\\ buttock\\ burning\\ pain\\ and\\ numbness\\ extending\\ into\\ lower\\ thigh\\.\\ \\ initially\\ treated\\ with\\ nsaids\\ and\\ physical\\ therapy\\,\\ symptoms\\ continued\\ to\\ worsen\\.\\ \\ presented\\ to\\ wramc\\ with\\ numbness\\ and\\ tingling\\ extending\\ into\\ left\\ testicle\\ and\\ penis\\.\\ \\ patient\\ denies\\ bowel\\ or\\ bladder\\ incontinence\\,\\ weight\\ loss\\,\\ or\\ other\\ constitutional\\ symptoms\\.\\ \\ denies\\ any\\ numbness\\,\\ pain\\,\\ or\\ abnormal\\ sensations\\ on\\ right\\ side\\.\ \(0\)\
\-\ pmhx\\:\\ htn\\,\\ hyperlipidemia\ \(0\)\
\-\ pshx\\:\\ remote\\ tonsillectomy\\/\\ bilateral\\ herniorrhaphy\ \(0\)\
\-\ meds\\:\\ ramipril\\ 5\\ mg\\ po\\ qd\\,\\ hctz\\ 12\\.5\\ mg\\ po\\ qd\\,\\ amitryptyline\\ 25\\ mg\\ po\\ qd\\,\\ zocor\\ 10\\ mg\\ po\\ qd\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ qd\\:\\ 0\\.07369234762900069\ \(0\)\
\-\ po\\:\\ 0\\.06383912145414604\ \(0\)\
\-\ mg\\:\\ 0\\.061286065868253685\ \(0\)\
\-\ sacrum\\:\\ 0\\.05276010999491521\ \(0\)\
\-\ chondrosarcoma\\:\\ 0\\.04188454550682838\ \(0\)\
\-\ penis\\:\\ 0\\.04137654754365031\ \(0\)\
\-\ numbness\\:\\ 0\\.040254786496609456\ \(0\)\
\-\ side\\:\\ 0\\.03869864708188328\ \(0\)\
\-\ infiltrating\\:\\ 0\\.03033419054948275\ \(0\)\
\-\ tonsillectomy\\/\\:\\ 0\\.02880888373845261\ \(0\)\
\-\ ramipril\\:\\ 0\\.02880888373845261\ \(0\)\
\-\ amitryptyline\\:\\ 0\\.02880888373845261\ \(0\)\
\-\ neural\\:\\ 0\\.028280274864276856\ \(0\)\
\-\ films\\-\\:\\ 0\\.026543696873877625\ \(0\)\
\-\ herniorrhaphy\\:\\ 0\\.026543696873877625\ \(0\)\
\-\ zocor\\:\\ 0\\.025218647500975126\ \(0\)\
\-\ left\\:\\ 0\\.024996216190141564\ \(0\)\
\-\ yields\\:\\ 0\\.024278510009302638\ \(0\)\
\-\ hctz\\:\\ 0\\.024278510009302638\ \(0\)\
\-\ denies\\:\\ 0\\.02356883837336652\ \(0\)\
\-\ initially\\:\\ 0\\.022731897674935816\ \(0\)\
\-\ sensations\\:\\ 0\\.022449700244807795\ \(0\)\
\-\ rate\\:\\ 0\\.02176942150637806\ \(0\)\
\-\ encroaching\\:\\ 0\\.021284095852851154\ \(0\)\
\-\ \\,\\:\\ 0\\.021232162001355873\ \(0\)\
\-\ wramc\\:\\ 0\\.020972624677020026\ \(0\)\
\-\ pshx\\:\\ 0\\.020688273771825156\ \(0\)\
\-\ worsen\\:\\ 0\\.02042669629576785\ \(0\)\
\-\ 12\\.5\\:\\ 0\\.02042669629576785\ \(0\)\
\-\ sphincter\\:\\ 0\\.020184513380232808\ \(0\)\
\-\ similarly\\:\\ 0\\.020184513380232808\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.020184513380232808\ \(0\)\
\-\ mri\\-\\:\\ 0\\.019959046479948655\ \(0\)\
\-\ into\\:\\ 0\\.019934572234899087\ \(0\)\
\-\ guaiac\\:\\ 0\\.01974813628015267\ \(0\)\
\-\ burning\\:\\ 0\\.01974813628015267\ \(0\)\
\-\ \\%\\:\\ 0\\.019542363072019682\ \(0\)\
\-\ employed\\:\\ 0\\.019186534133333523\ \(0\)\
\-\ locally\\:\\ 0\\.019186534133333523\ \(0\)\
\-\ chondroma\\:\\ 0\\.019186534133333523\ \(0\)\
\-\ si\\:\\ 0\\.019018908988276167\ \(0\)\
\-\ high\\-grade\\:\\ 0\\.019018908988276167\ \(0\)\
\-\ chondroid\\:\\ 0\\.019018908988276167\ \(0\)\
\-\ recur\\:\\ 0\\.01885946400733031\ \(0\)\
\-\ 10\\:\\ 0\\.018827609335600723\ \(0\)\
\-\ extending\\:\\ 0\\.01877594149568495\ \(0\)\
\-\ buttock\\:\\ 0\\.018707437812445042\ \(0\)\
\-\ ct\\-\\:\\ 0\\.01856217061450114\ \(0\)\
\-\ constitutional\\:\\ 0\\.018423086907250173\ \(0\)\
\-\ ill\\:\\ 0\\.018161509431192862\ \(0\)\
\-\ normal\\:\\ 0\\.01751127391632812\ \(0\)\
\-\ radical\\:\\ 0\\.017482949415577684\ \(0\)\
\-\ scrotum\\:\\ 0\\.017382388439542543\ \(0\)\
\-\ hyperlipidemia\\:\\ 0\\.01728482973643901\ \(0\)\
\-\ meds\\:\\ 0\\.017190099223781324\ \(0\)\
\-\ established\\:\\ 0\\.017098037534347674\ \(0\)\
\-\ foramina\\:\\ 0\\.01692134726875854\ \(0\)\
\-\ only\\:\\ 0\\.016793540251535528\ \(0\)\
\-\ sacral\\:\\ 0\\.016753722123701183\ \(0\)\
\-\ tingling\\:\\ 0\\.016753722123701183\ \(0\)\
\-\ widened\\:\\ 0\\.016594277142755326\ \(0\)\
\-\ primary\\:\\ 0\\.016544995182324815\ \(0\)\
\-\ incontinence\\:\\ 0\\.016517380092395215\ \(0\)\
\-\ pmhx\\:\\ 0\\.016517380092395215\ \(0\)\
\-\ myeloma\\:\\ 0\\.016226702033517778\ \(0\)\
\-\ remote\\:\\ 0\\.01615790004267519\ \(0\)\
\-\ value\\:\\ 0\\.015834073563445676\ \(0\)\
\-\ temperature\\:\\ 0\\.015772988161445175\ \(0\)\
\-\ tone\\:\\ 0\\.015654139651082838\ \(0\)\
\-\ borders\\:\\ 0\\.015539462135359736\ \(0\)\
\-\ testicle\\:\\ 0\\.015539462135359736\ \(0\)\
\-\ erosions\\:\\ 0\\.015483597974054833\ \(0\)\
\-\ htn\\:\\ 0\\.015374655424160742\ \(0\)\
\-\ modality\\:\\ 0\\.015321516467063421\ \(0\)\
\-\ diminished\\:\\ 0\\.015269227769852829\ \(0\)\
\-\ thigh\\:\\ 0\\.015269227769852829\ \(0\)\
\-\ presented\\:\\ 0\\.015224559706028819\ \(0\)\
\-\ touch\\:\\ 0\\.015068058184887361\ \(0\)\
\-\ nsaids\\:\\ 0\\.015068058184887361\ \(0\)\
\-\ managed\\:\\ 0\\.015019642871864025\ \(0\)\
\-\ survival\\:\\ 0\\.014971934377023656\ \(0\)\
\-\ therapy\\:\\ 0\\.01493229278588636\ \(0\)\
\-\ lucent\\:\\ 0\\.014924912359206337\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.014529642390521166\ \(0\)\
\-\ choice\\:\\ 0\\.014447938788542678\ \(0\)\
\-\ s1\\:\\ 0\\.014407840446739362\ \(0\)\
\-\ metastatic\\:\\ 0\\.01405953858572608\ \(0\)\
\-\ response\\:\\ 0\\.013996467094160922\ \(0\)\
\-\ five\\:\\ 0\\.013926933112307052\ \(0\)\
\-\ symptoms\\:\\ 0\\.013919329914366924\ \(0\)\
\-\ overall\\:\\ 0\\.013892713178100204\ \(0\)\
\-\ hx\\:\\ 0\\.013825329886587995\ \(0\)\
\-\ epidural\\:\\ 0\\.013759307967249695\ \(0\)\
\-\ 65\\:\\ 0\\.013631135702042895\ \(0\)\
\-\ 17\\:\\ 0\\.013599862986303841\ \(0\)\
\-\ surgery\\:\\ 0\\.013562085387975653\ \(0\)\
\-\ giant\\:\\ 0\\.013447836791418569\ \(0\)\
\-\ foramen\\:\\ 0\\.013331111031281056\ \(0\)\
\-\ 90\\:\\ 0\\.013163485886223701\ \(0\)\
\-\ bodies\\:\\ 0\\.013082791073836864\ \(0\)\
\-\ light\\:\\ 0\\.013030080675373194\ \(0\)\
\-\ tumor\\:\\ 0\\.013021126154319027\ \(0\)\
\-\ 45\\:\\ 0\\.012901908410166392\ \(0\)\
\-\ sensation\\:\\ 0\\.012827350639688708\ \(0\)\
\-\ joints\\:\\ 0\\.012778574004993689\ \(0\)\
\-\ lower\\:\\ 0\\.012561189995842239\ \(0\)\
\-\ continued\\:\\ 0\\.012025228715412537\ \(0\)\
\-\ limited\\:\\ 0\\.01178441918668326\ \(0\)\
\-\ defined\\:\\ 0\\.011766610020776185\ \(0\)\
\-\ excision\\:\\ 0\\.011461603681585926\ \(0\)\
\-\ bladder\\:\\ 0\\.011334676121728855\ \(0\)\
\-\ 25\\:\\ 0\\.01128832110541527\ \(0\)\
\-\ \\:\\:\\ 0\\.011081125646967303\ \(0\)\
\-\ vertebral\\:\\ 0\\.011051622288928949\ \(0\)\
\-\ tumors\\:\\ 0\\.010489269142714057\ \(0\)\
\-\ occur\\:\\ 0\\.010477276564645551\ \(0\)\
\-\ metastasis\\:\\ 0\\.010453422634967081\ \(0\)\
\-\ intensity\\:\\ 0\\.01009369502084739\ \(0\)\
\-\ otherwise\\:\\ 0\\.010030441939301782\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.010009626748826357\ \(0\)\
\-\ weight\\:\\ 0\\.010009626748826357\ \(0\)\
\-\ or\\:\\ 0\\.009818850480036348\ \(0\)\
\-\ being\\:\\ 0\\.009731333257518165\ \(0\)\
\-\ neoplasm\\:\\ 0\\.00951031560755532\ \(0\)\
\-\ week\\:\\ 0\\.00948371051741251\ \(0\)\
\-\ white\\:\\ 0\\.00926177847291509\ \(0\)\
\-\ space\\:\\ 0\\.009237114402211224\ \(0\)\
\-\ along\\:\\ 0\\.009228934238099727\ \(0\)\
\-\ is\\:\\ 0\\.009187757816743884\ \(0\)\
\-\ radiation\\:\\ 0\\.009164219769811558\ \(0\)\
\-\ plain\\:\\ 0\\.009069489257153871\ \(0\)\
\-\ body\\:\\ 0\\.009069489257153871\ \(0\)\
\-\ area\\:\\ 0\\.008829530209589109\ \(0\)\
\-\ any\\:\\ 0\\.00879357853945194\ \(0\)\
\-\ bowel\\:\\ 0\\.008758018081322743\ \(0\)\
\-\ approximately\\:\\ 0\\.008639927537763343\ \(0\)\
\-\ treated\\:\\ 0\\.00835898966040477\ \(0\)\
\-\ negative\\:\\ 0\\.008340261965277367\ \(0\)\
\-\ 5\\:\\ 0\\.008170458896876351\ \(0\)\
\-\ pulmonary\\:\\ 0\\.008158661144510011\ \(0\)\
\-\ loss\\:\\ 0\\.008106092066890325\ \(0\)\
\-\ when\\:\\ 0\\.007997814502013091\ \(0\)\
\-\ two\\:\\ 0\\.007997814502013091\ \(0\)\
\-\ lymphoma\\:\\ 0\\.007981041288854528\ \(0\)\
\-\ abnormal\\:\\ 0\\.007964353726519319\ \(0\)\
\-\ following\\:\\ 0\\.007925744303598525\ \(0\)\
\-\ t2\\:\\ 0\\.00790388486519723\ \(0\)\
\-\ y\\/o\\:\\ 0\\.007734081796796212\ \(0\)\
\-\ high\\:\\ 0\\.007642307389139921\ \(0\)\
\-\ cell\\:\\ 0\\.007543270299285903\ \(0\)\
\-\ signal\\:\\ 0\\.007362988007427382\ \(0\)\
\-\ over\\:\\ 0\\.007109943105032558\ \(0\)\
\-\ on\\:\\ 0\\.007096970709464981\ \(0\)\
\-\ \\)\\:\\ 0\\.006995467569738285\ \(0\)\
\-\ bone\\:\\ 0\\.00693932902437866\ \(0\)\
\-\ physical\\:\\ 0\\.006851324410396204\ \(0\)\
\-\ pain\\:\\ 0\\.00682096841523356\ \(0\)\
\-\ bilateral\\:\\ 0\\.0067771821219426275\ \(0\)\
\-\ 1\\:\\ 0\\.006644857411633029\ \(0\)\
\-\ 3\\:\\ 0\\.0065391357081913066\ \(0\)\
\-\ other\\:\\ 0\\.006436727283341335\ \(0\)\
\-\ well\\:\\ 0\\.006317258016237422\ \(0\)\
\-\ exam\\:\\ 0\\.006134751437743589\ \(0\)\
\-\ 2\\:\\ 0\\.006013413387289367\ \(0\)\
\-\ but\\:\\ 0\\.0059558931406324764\ \(0\)\
\-\ multiple\\:\\ 0\\.005881718965618526\ \(0\)\
\-\ lesion\\:\\ 0\\.005688088973857695\ \(0\)\
\-\ treatment\\:\\ 0\\.005652343005231657\ \(0\)\
\-\ within\\:\\ 0\\.0053272268247911165\ \(0\)\
\-\ male\\:\\ 0\\.00504969130028586\ \(0\)\
\-\ for\\:\\ 0\\.004765412736226896\ \(0\)\
\-\ disease\\:\\ 0\\.004564501768678772\ \(0\)\
\-\ as\\:\\ 0\\.004224109496386038\ \(0\)\
\-\ to\\:\\ 0\\.00418694223963712\ \(0\)\
\-\ and\\:\\ 0\\.0041178530723056505\ \(0\)\
\-\ not\\:\\ 0\\.004035355136411554\ \(0\)\
\-\ mass\\:\\ 0\\.0038838594998286424\ \(0\)\
\-\ of\\:\\ 0\\.0034265823764114242\ \(0\)\
\-\ year\\:\\ 0\\.0031245270237676955\ \(0\)\
\-\ right\\:\\ 0\\.0029465088533020154\ \(0\)\
\-\ patient\\:\\ 0\\.0027993200356744704\ \(0\)\
\-\ with\\:\\ 0\\.0022941995311743083\ \(0\)\
\-\ the\\:\\ 0\\.0022589752402553238\ \(0\)\
\-\ a\\:\\ 0\\.0012960777837209192\ \(0\)\
\-\ \\.\\:\\ 0\\.0012761271146104868\ \(0\)\
